相关实验视频

Updated: Jun 4, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

新型PD-L1/VISTA双抑制剂作为潜在的免疫治疗剂

Chengliang Sun^1,2,3, Yao Cheng^1,4, Jingwen Dong⁵

¹State Key Laboratory of Natural Medicines and Jiangsu Key Laboratory of Drug Design and Optimization, China Pharmaceutical University, Nanjing 210009, China.

Journal of medicinal chemistry

|December 28, 2024

概括

一种新型的双抑制剂,P17,有效地阻断PD-L1和VISTA免疫检查点,恢复T细胞抗瘤活性. 这种有前途的候选药物在临床前模型中显示出卓越的疗效并增强免疫细胞透.

科学领域:

免疫学免疫学免疫学
药理学药理学是指药理学的学科.
在瘤学瘤学.

背景情况:

免疫检查点抑制剂 (ICI) 对癌症免疫疗法至关重要.
PD-L1和VISTA是关键的免疫调节蛋白质,在瘤中常常受到上调.
针对这些检查点可以恢复抗瘤免疫反应.

研究的目的:

确定和描述PD-L1和VISTA的新型双抑制剂.
为了评估已识别的抑制剂的疗效和安全性,P17.
评估PD-L1和VISTA在癌症治疗中的双重向潜力.

主要方法:

合理的药物设计被用来识别P17.
在体外测试中评估了P17对PD-L1和VISTA信号传输的抑制作用.
在体内实验中评估了P17的抗瘤功效和免疫细胞透.

主要成果:

确定P17是PD-L1和VISTA的双重抑制剂.
在蛋白质和细胞水平上,P17有效地阻断了PD-L1和VISTA,重新激活了T细胞.
与单位抑制剂相比,P17在体内表现出优异的抗瘤疗效和增强的免疫细胞透.
P17表现出有利的药物可用性和安全性.

结论:

双重准PD-L1和VISTA是一种可行的治疗策略.
P17是一种有前途的候选药物,在癌症治疗中具有显著的治疗潜力.
P17需要进一步研究其在免疫治疗中的临床应用.

更多相关视频

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells

Published on: February 8, 2018

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Cancer Vaccines

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...